Five years after Novartis made history with the approval of the first CAR-T, Kymriah, we’re getting a clearer picture of just how important the advance was for some patients.
The pharma giant may still be having trouble manufacturing the treatment or reaching long-cherished goals of blockbuster revenue, but a new...
